?A Phase 1/2, Dose Escalation And Expansion Study Of The Safety, Tolerability, And Anti-Tumor Activity Of BND-22 Administered Alone And In Combination With Pembrolizumab Or With Cetuximab In Patients With Advanced Solid Tumors